S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:CKPT

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

$5.67
+0.20 (+3.66%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.40
$5.67
50-Day Range
$0.52
$7.73
52-Week Range
$3.56
$24.10
Volume
84,162 shs
Average Volume
253,416 shs
Market Capitalization
$52.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Checkpoint Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
702.5% Upside
$45.50 Price Target
Short Interest
Healthy
4.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.63
Upright™ Environmental Score
News Sentiment
0.21mentions of Checkpoint Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$102,359 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.91) to ($4.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

147th out of 1,026 stocks

Pharmaceutical Preparations Industry

57th out of 504 stocks

CKPT stock logo

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Stock News Headlines

New Years, New Ways To Trade!
If you’ve been considering options trading but don’t know where to start, trading champion Chuck Hughes’ coveted guide, “Options Trading Made Easy” is for you! Free for a limited time, this guide could help 2023 become your most profitable year yet! Click here for a free copy now! pixel
Checkpoint Therapeutics: An Updated Analysis
3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
Checkpoint Therapeutics Announces Reverse Stock Split
Checkpoint: Strong Data, But Comes With Risks
See More Headlines
Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Company Calendar

Last Earnings
11/04/2021
Today
2/08/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CKPT
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.50
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+164.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,670,000.00
Net Margins
-53,252.24%
Pretax Margin
-53,252.24%

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$3.43 per share

Miscellaneous

Free Float
8,902,000
Market Cap
$52.73 million
Optionable
Not Optionable
Beta
1.49

Key Executives

  • James F. Oliviero
    President, Chief Executive Officer & Director
  • William Garrett GrayWilliam Garrett Gray
    Chief Financial Officer, Secretary & Treasurer
  • Jaclyn Jaffe
    Head-Investor Relations













CKPT Stock - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings
or view top-rated stocks.

What is Checkpoint Therapeutics' stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Checkpoint Therapeutics' shares. Their CKPT share price forecasts range from $15.00 to $76.00. On average, they predict the company's share price to reach $45.50 in the next year. This suggests a possible upside of 702.5% from the stock's current price.
View analysts price targets for CKPT
or view top-rated stocks among Wall Street analysts.

How have CKPT shares performed in 2023?

Checkpoint Therapeutics' stock was trading at $5.11 on January 1st, 2023. Since then, CKPT shares have increased by 11.0% and is now trading at $5.67.
View the best growth stocks for 2023 here
.

When is Checkpoint Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CKPT earnings forecast
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). The firm earned $0.03 million during the quarter, compared to the consensus estimate of $0.30 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 508.89% and a negative net margin of 53,252.24%.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Park Avenue Securities LLC (0.50%), Envestnet Asset Management Inc. (0.30%), Ironwood Investment Management LLC (0.14%), Emfo LLC (0.08%), Bartlett & Co. LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends
.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $5.67.

How much money does Checkpoint Therapeutics make?

Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $52.73 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($8.70) on an earnings per share basis.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com.

This page (NASDAQ:CKPT) was last updated on 2/9/2023 by MarketBeat.com Staff